中国癌症杂志 ›› 2016, Vol. 26 ›› Issue (6): 533-537.doi: 10.19401/j.cnki.1007-3639.2016.06.009

• 论著 • 上一篇    下一篇

EB病毒编码的小mRNA阴性结外NK/T细胞淋巴瘤的临床特征及预后分析

贾思思1,2,南飞飞1,2,李素彩1,2,曹婧语1,2,王冠男3,张明智1,2,张 蕾1,2   

  1. 1. 郑州大学第一附属医院肿瘤内科,河南 郑州 450052 ;
    2. 河南省淋巴瘤诊疗中心,河南 郑州 450052 ;
    3. 郑州大学第一附属医院病理科,河南 郑州 450052
  • 出版日期:2016-06-30 发布日期:2016-07-28
  • 通信作者: 张 蕾 E-mail: zl2909@163.com
  • 基金资助:
    河南省科技计划项目(142300410389)。

The clinical features and prognosis of EBER negative extranodal natural killer/T-cell lymphoma

JIA Sisi1,2, NAN Feifei1,2, LI Sucai1,2, CAO Jingyu1,2, WANG Guannan3, ZHANG Mingzhi1,2, ZHANG Lei1,2   

  1. 1.Department of Oncology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, China; 2.Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou 450052, Henan Province, China; 3.Department of Pathology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, China
  • Published:2016-06-30 Online:2016-07-28
  • Contact: ZHANG Lei E-mail: zl2909@163.com

摘要: 背景与目的:结外NK/T细胞淋巴瘤(extranodal natural killer/T-cell lymphoma,ENKTL)为非霍奇金淋巴瘤的一个亚型,中国发病率远高于西方国家。该病恶性程度高,对化疗不敏感,生存期短,预后差,EB病毒(Epstein-Barr virus,EBV)感染与该病的发生、发展有密切关系,但仍有少数患者无EBV感染。本研究探讨EBV编码的小mRNA(EBV-encoded small RNA,EBER)原位杂交阴性患者的临床特征及预后相关因素。方法:选取2011年8月—2015年10月郑州大学第一附属医院病理科诊断为ENKTL的326例标本,采用原位杂交技术检测其EBER表达,回顾性分析8例EBER阴性患者临床特征及预后相关因素。结果:326例ENKTL中,EBER表达阴性率为2.45%(8/326),8例EBER表达阴性患者的中位生存期为17个月。EBER阴性与EBER阳性患者的生存率log-rank检验,两条生存曲线差异有统计学意义(χ2=6.407,P=0.011)。多变量Cox比例风险回归分析表明,乳酸脱氢酶(lactate dehydrogenase,LDH)与EBER阴性ENKTL患者预后有关(P=0.008),血浆中EBV-DNA拷贝数与EBER阴性患者的预后无关(P>0.05)。结论:EBER表达阴性ENKTL发病率低,预后较EBER阳性患者差,LDH升高可能是其预后不良因素。

关键词: 结外NK/T细胞淋巴瘤, EB病毒编码的小mRNA阴性, 临床特征, 预后

Abstract:

Background and purpose: Extranodal natural killer/T-cell lymphoma (ENKTL) is a form of non-Hodgkin’s lymphoma. The ENKTL incidence in China is much higher than that in the Western countries. The disease is highly malignant, not sensitive to chemotherapy, has short survival period and poor prognosis. Epstein-Barr virus (EBV) infection has close relationship with the development of the disease. However, there are still a few patients without EBV infection. This study aimed to discuss the clinical features and prognosis of EBV-encoded small RNA (EBER) in situ hybridization negative ENKTL. Methods: From Aug. 2011 to Oct. 2015, 326 cases were diagnosed with ENKTL from the First Affiliated Hospital of Zhengzhou University. The expression of EBER was detected by in situ hybridization technique. The clinical pathological characteristics and prognosis of EBER-negative patients were analyzed. Results: In 326 patients with ENKTL, the negative rate of EBER was 2.45% (8/326). In 8 EBER-negative patients, the median survival time was 17 months. The log-rank test revealed that there was a significant difference between EBER-negative and EBER-positive curves (χ2=6.407, P=0.011). Multivariate Cox proportional hazards regression analysis showed that in EBER-negative ENKTL, only lactate dehydrogenase (LDH) predicted survival time (P=0.008). EBV-DNA copy number in plasma was not significantly correlated with survival time (P>0.05). Conclusion: The incidence of EBER-negative ENKTL is low. Patients with EBER-negative ENKTL have poorer prognosis than EBER-positive patients. Elevated LDH may be a factor indicating poor prognosis.

Key words: Extranodal NK/T-cell lymphoma, EB virus-encoded small RNA negative, Clinical features, Prognosis